Enhertu (Trastuzumab Deruxtecan): targeted therapy for HER2-positive and HER2-low cancers
Enhertu, also known as trastuzumab deruxtecan, represents a significant advancement in cancer treatment. As a next-generation smart drug, it allows therapies to target tumors with greater precision and effectiveness. At Biruni Hospital, patients with HER2-positive and HER2-low cancers now have access to this innovative therapy, offering new treatment possibilities. While Turkey continues to make progress in adopting such therapies, challenges remain in balancing access and treatment outcomes.
What is Enhertu (Trastuzumab Deruxtecan)?
Enhertu is a targeted cancer therapy that combines a HER2-specific antibody with a chemotherapy payload, delivering the drug directly to cancer cells. This targeted mechanism maximizes tumor impact while minimizing damage to healthy tissue. Initially approved for certain breast and gastric cancers, its use is expanding to other HER2-expressing tumors.
Key Features:
Combines a HER2-targeting antibody with a chemotherapy agent
Selectively attacks HER2-expressing cancer cells
Used in metastatic HER2-positive and HER2-low breast cancers
Approved in specific cases for HER2-positive gastric cancer
Administered intravenously, typically every three weeks
Requires regular monitoring for side effects, including lung toxicity and changes in blood counts
Development, variants, and clinical applications of Trastuzumab Deruxtecan
DS-8201a
DS-8201a was the original research designation for what later became Enhertu. In clinical studies, the term often refers to early or slightly modified versions of the drug. DS-8201a played a foundational role in the development of trastuzumab deruxtecan, demonstrating that coupling a HER2-targeting antibody with a potent chemotherapy payload could effectively kill cancer cells while maintaining a manageable safety profile.
Clinical trials of DS-8201a helped establish: dosing schedules, safety monitoring protocols, and patient selection criteria that continue to guide the use of trastuzumab deruxtecan today.
Key Features of DS-8201a:
Used primarily in clinical trial settings before regulatory approval
Administered intravenously every three weeks or per study protocol
Requires careful monitoring of heart and lung function
Common side effects include nausea, fatigue, and potential lung inflammation
Provided early evidence of efficacy in HER2-positive breast and gastric cancers
Trastuzumab Emtansine (T-DM1)
Trastuzumab emtansine, also known as T-DM1, is a predecessor HER2-targeted antibody-drug conjugate. It combines the same HER2-targeting antibody used in trastuzumab deruxtecan with a different chemotherapy payload. T-DM1 was among the first ADCs approved for HER2-positive breast cancer and established the concept of targeted chemotherapy delivery directly to tumor cells.
T-DM1 remains an important treatment option and served as a critical stepping stone toward the development of more advanced HER2-targeted therapies like Enhertu.
Key Features of T-DM1:
Administered intravenously, typically every three weeks
Requires regular cardiac monitoring due to potential heart effects
Common side effects include fatigue, nausea, and low platelet counts
Approved for early and metastatic HER2-positive breast cancer
Dosing adjusted based on patient tolerance and laboratory results
Investigational Trastuzumab Deruxtecan Variants
Several biotech companies are developing new variants of trastuzumab deruxtecan. These experimental ADCs aim to improve tumor targeting, reduce toxicity, or overcome resistance observed in some patients. While not yet widely available, these variants represent the next generation of HER2-targeted therapies and highlight the progress of personalized medicine.
Key Features of Investigational Variants:
Available only in clinical trials with strict eligibility criteria
Intravenous dosing schedules vary depending on study design
Intensive monitoring of heart and lung function is required
Focused on safety, tolerability, and efficacy against resistant HER2-positive tumors
May be combined with other therapies in trials to enhance response
Combination Therapies Involving Trastuzumab Deruxtecan
Trastuzumab deruxtecan is also being tested in combination with other smart drugs, such as immunotherapies or targeted agents. These combinations aim to leverage different mechanisms of action for stronger or more durable cancer control. They underscore the personalized approach required in modern oncology, where treatment regimens must be tailored to tumor biology and patient characteristics.
Key Features of Combination Therapies:
Administered in hospital or clinical settings under careful supervision
Treatment schedules depend on the combination drugs and patient condition
Side effects are closely monitored as combinations may increase toxicity
Clinical trials evaluate improvements in survival and quality of life
Dose adjustments or treatment breaks may be applied to manage side effects
What are the types of cancer treated with enhertu (Trastuzumab Deruxtecan)?
The therapeutic use of trastuzumab deruxtecan continues to expand as research advances in HER2-driven cancers. Beyond its established indications, this treatment is being evaluated in several solid tumors that exhibit HER2 overexpression or genetic alterations, particularly in advanced or treatment-resistant settings.
Colorectal cancer with HER2 Overexpression
A subset of patients with advanced colorectal cancer presents HER2 amplification, which may make them eligible for treatment with Enhertu under specific clinical conditions.
Although this indication remains under active investigation, early clinical data suggest potential benefit in patients whose disease has progressed despite standard chemotherapy and targeted therapies.
This targeted approach offers an additional therapeutic option in metastatic and resistant colorectal cancer cases.
Key aspects of Enhertu in colorectal cancer:
HER2 testing on tumor tissue required to confirm eligibility
Mainly considered in metastatic disease unresponsive to chemotherapy or EGFR inhibitors
Administered intravenously every three weeks with close clinical monitoring
Periodic lung imaging recommended to detect inflammatory changes
Possible side effects include fatigue, diarrhea, and decreased white blood cell counts
Uterine or endometrial cancer with HER2 expression
In rare and aggressive subtypes of uterine or endometrial cancer, HER2 overexpression has been identified as a potential therapeutic target.
Trastuzumab deruxtecan is being studied in high-grade or recurrent endometrial tumors, particularly when standard treatment options are no longer effective or well tolerated.
This reflects the broader recognition of HER2 as a clinically relevant target beyond breast cancer.
Key aspects of Enhertu in uterine cancer:
HER2 status confirmed through biopsy and immunohistochemistry analysis
Treatment cycles generally administered every three weeks with premedication
Regular monitoring of lung and cardiac function throughout therapy
Typically reserved for patients with multiple prior lines of treatment
May help delay disease progression and achieve tumor reduction in selected cases
Biliary tract cancers with HER2 Alterations
Biliary tract cancers are often difficult to treat and respond poorly to conventional systemic therapies.
In a limited number of cases, HER2 amplification or mutations are detected, allowing trastuzumab deruxtecan to be considered within clinical trials or specialized oncology programs.
This targeted strategy offers a potential option for patients with advanced disease and limited therapeutic alternatives.
Key aspects of Enhertu in biliary tract cancers:
Primarily used in clinical trial settings or specialized cancer centers
HER2 alterations confirmed through molecular profiling or next-generation sequencing
Intravenous administration every three weeks in a monitored hospital environment
Treatment response assessed through imaging studies and tumor markers
Dose modifications may be necessary based on tolerance and laboratory results
Salivary gland cancers with HER2 Positivity
Certain rare salivary gland tumors demonstrate HER2 overexpression and share biological characteristics with aggressive HER2-positive malignancies.
Trastuzumab deruxtecan is currently being evaluated in early-phase trials and expanded access programs for patients with advanced or unresectable disease.
This approach introduces targeted therapy into a field with historically limited treatment options.
Key aspects of Enhertu in salivary gland cancers:
Comprehensive HER2 testing required before initiating treatment
Administered intravenously every three weeks under specialist supervision
Baseline and ongoing cardiac assessment recommended
Considered in advanced cases where surgery or radiotherapy is no longer effective
Safety profile similar to other indications, with reinforced monitoring for lung toxicity
What are the side effects of Enhertu trastuzumab deruxtecan?
Like all targeted cancer therapies, Enhertu (trastuzumab deruxtecan) may cause side effects that vary in type and intensity from one patient to another. Close medical monitoring allows early detection and appropriate management throughout treatment.
Fatigue
Fatigue is one of the most frequently reported side effects. Patients may experience persistent tiredness, reduced energy levels, or difficulty concentrating.
This symptom can gradually increase over time and may also be influenced by the underlying disease or previous treatments. Adequate rest, energy conservation, and treatment adjustments often help manage fatigue effectively.
Nausea and vomiting
Nausea and vomiting are common, particularly during the first treatment cycles. Symptoms may range from mild stomach discomfort to more significant episodes that affect appetite and hydration.
Preventive anti-nausea medications are routinely prescribed before and after infusions to reduce severity and improve patient comfort.
Low white blood cell count
Enhertu can lower white blood cell levels, which play a key role in protecting the body against infections. A reduced count may increase the risk of fever or illness.
Blood tests are performed regularly, and treatment schedules may be adjusted or supportive medications prescribed if levels drop below safe thresholds.
Lung inflammation
Interstitial lung disease is a rare but potentially serious side effect associated with Enhertu. Symptoms may include persistent cough, shortness of breath, or chest discomfort.
Immediate medical evaluation is essential if respiratory symptoms occur, as early intervention significantly improves outcomes in most cases.
Hair thinning or hair loss
Hair thinning may occur during treatment, although it is generally less pronounced than with traditional chemotherapy.
The degree of hair changes varies between patients and may become more noticeable after several treatment cycles.
Anemia
A decrease in red blood cell levels may lead to symptoms such as weakness, shortness of breath, or paleness, especially during physical activity.
Routine blood monitoring allows early detection, and in more severe cases, medical treatment or transfusion may be required.
Diarrhea
Digestive disturbances, including diarrhea or abdominal cramping, may develop as the body adapts to treatment.
Maintaining hydration, dietary adjustments, and prescribed medications usually help control symptoms effectively.
Liver enzyme change
Some patients may experience temporary elevations in liver enzyme levels detected through routine blood tests.
These changes are often mild and asymptomatic but require monitoring. Dosage adjustments may be considered if abnormalities persist.
Where precision meets possibility
Advances in targeted therapies illustrate how cancer treatment continues to evolve toward greater accuracy and personalization. Enhertu reflects this progress by focusing on tumor-specific characteristics rather than broad, non-selective approaches.
Rather than treating cancer in a generalized way, this strategy prioritizes precision, timing, and biological alignment with the tumor profile. For patients facing complex or treatment-resistant cancers, this approach may offer renewed therapeutic potential and improved disease control within a carefully monitored clinical framework.